Fosamprenavir: A review of its use in the management of antiretroviral therapy-naive patients with HIV infection

Drugs

Volumn 64, Issue 18, 2004, Pages 2101-2124

  Chapman, Therese M ^a   Plosker, Greg L ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; BENZODIAZEPINE DERIVATIVE; DELAVIRDINE; EFAVIRENZ; ERGOT DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; LOPINAVIR; METHADONE; NELFINAVIR; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PRAVASTATIN; PRODRUG; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; UNINDEXED DRUG; VIRUS RNA;

ABDOMINAL PAIN; ADULT; CLINICAL TRIAL; CROSS RESISTANCE; CUSHINGOID SYNDROME; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; INSOMNIA; LIPODYSTROPHY; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; OBESITY; PATIENT COMPLIANCE; PRURITUS; RASH; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS ISOLATION; VIRUS LOAD; VOMITING;

ANTI-RETROVIRAL AGENTS; CARBAMATES; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; PHOSPHORIC ACID ESTERS; SULFONAMIDES;

HUMAN IMMUNODEFICIENCY VIRUS; MURINAE; RNA VIRUSES;

EID: 4644305654     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464180-00014     Document Type: Review

References (40)

1. Panel on Clinical Practices for Treatment of HIV Infection convened by the US Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents: March 23, 2004 [online]. Available from URL: http://aidsinfo.nih.gov/guidelines/adult/ AA_071403.pdf [Accessed 2004 Apr 22]
2. British HIV Association Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001 Oct; 2 (4): 276-313
3. European AIDS Clinical Society. Euroguidelines: European guidelines for the clinical management and treatment of HIV infected adults in Europe 2001 [online]. Available from URL: http://www.eacs.ws/download/European_Treatment_ Guidelines.pdf [Accessed 2003 Sep 10]
4. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002 Jul 10; 288 (2): 222-35
5. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998 Mar 26; 338 (13): 853-60
6. Noble S, Goa KL. Amprenavir: a review of its clinical potential in patients with HIV infection. Drugs 2000 Dec; 60 (6): 1383-410
7. Baker C, Chaturvedi PR, Hale MR, et al. Discovery of VX-175/ GW433908, a novel, water-soluble prodrug of amprenavir [abstract no. 916]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 313
8. GlaxoSmithKline. Agenerase® (amprenavir) capsules: prescribing information (US) [online]. Available from URL: http:// us.gsk.com/products/ assets/us_agenerase_capsules.pdf [Accessed 2003 Aug 28]
9. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003 Apr; 17 (4): 169-77
10. Agouron Pharmaceuticals Inc. Viracept® (nelfinavir mesylate) tablets and oral powder: prescribing information (US) [online]. Available from URL: http://www.viracept.com/brochures/ PI.pdf [Accessed 2003 Oct 8]
11. Roche Laboratories Inc. Invitase® (saquinavir mesylate): U.S. FDA approves Invirase® boosted with ritonavir use in treatment of HIV/AIDS [online]. Available from URL: http:// www.fortovase.com [Accessed 2004 Apr 20]
12. DeJesus E, LaMarca A, Sension M, et al. The Context study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results) [abstract no. 178]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston
13. GlaxoSmithKline. Lexiva™ (fosamprenavir calcium) tablets: prescribing information (US) [online]. Available from URL: http://us.gsk.com/ products/assets/us_lexiva.pdf [Accessed 2004 Apr 161
14. Sadler BM, Gillotin C, Lou Y, et al. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001 Jan; 45 (1): 30-7
15. Gathe Jr JC, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004; 18: 1529-37
16. Caron M, Auclair M, Sterlingot H, et al. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003; 17: 2437-44
17. Dubé MP, Qian D, Edmondson-Melanqon H. et al. Prospective. intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002; 35: 475-81
18. Maguire M, Shortino D, Klein A, et al. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and infulence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 2002 Mar; 46 (3): 731-8
19. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004 Jan 1; 35 (1): 22-32
20. MacManus S, Yates P, White S, et al. GW433908 in ART-naive subjects: absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen [abstract no. 598 plus poster]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston
21. MacManus S, Yates PJ, Elston RC, et al. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 2004; 18: 651-5
22. Mo H, Lu L, Dekhtyar T, et al. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ ritonavir. Antiviral Res 2003 Aug; 59 (3): 173-80
23. Prado JG, Wrin T, Beauchaine J, et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002 May 3; 16 (7): 1009-17
24. Elston R, Yates P, Xu F. Long term follow up of treatment with the protease inhibitor GW433908 (908) in ART naive subjects [poster no. 3.10]. 2nd European HIV Drug Resistance Workshop; 2004 Mar 11-14; Rome
25. Nadler J, Rodriguez-French A, Gray G. et al. Long-term follow-up on unboosted GW433908 (908) bid: sustained virologic and immunologic response in antiretroviral treatment (ART)-naïve subjects over 96 weeks [poster no. TuPeB 4506]. XV International AIDS Conference; 2004 Jul 11-16; Bangkok
26. Ross L, Parkin N, Chappey C, et al. HIV clinical isolates containing mutations representative of those selected after first-line failure with unboosted GW433908 reamin sensitive to other protease inhibitors [poster no. 19]. XII International HIV Drug Resistance Workshop; 2003 Jun 10-14; Cabo del Sol, Los Cabos
27. Gathe J, Wood R, Bellow N, et al. Long-term follow-up on GW433908/ritonavir (908/r) qd: sustained virologic and immunologic response in antiretroviral treatment (ART)-naïve subjects over 96 weeks [poster no. TuPeB 4507]. XV International AIDS Conference; 2004 Jul 11-16; Bangkok
28. Falcoz C, Jenkins JM, Bye C, et al. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol 2002 Aug; 42 (8): 887-98
29. Wire MB, Mydlow P, Lou Y, et al. A phase I, single-dose, open-label, randomized, four-period, balanced crossover study to assess the relative bioavailability of the GW433908 oral suspension relative to the GW433908 oral film-coated 700mg tablet and to assess the effects of food on amprenavir pharmacokinetics following administration of these formulations to healthy adult subjects. Research Triangle Park (NC): GlaxoSmithKline, 2002. (Data on file)
30. Wood R, Arasteh K, Stellbrink H-J, et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2004 Jan; 48 (1): 116-23
31. Wood R, Arasteh K, Pollard R, et al. GW433908, a novel prodrug of the HIV protease inhibitor (PI) amprenavir (APV): safety, efficacy, and pharmacokinetics (PK) (APV20001) [poster no. 333]. 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4-8; Chicago
32. Wire MB, Ballow C, Preston SL, et al. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS 2004; 18: 897-907
33. Wire MB, Naderer OJ, Masterman AL, et al. The pharmacokinetic interaction between GW433908 and lopinavir/ritonavir (APV 10011 and APV10012) [abstract no. 612 plus poster]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco
34. Kashuba ADM, Tierney C, Downey GF, et al. Combining GW433908 (fosamprenavir; 908) with lopinavir/ritonavir (LPV/R) in HIV-1 infected adults results in substantial reductions in amprenavir (APV) and LPV concentrations: pharmacokinetic (PK) results from adult ACTG protocol A5143 [abstract no. H-855a plus poster]. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago
35. Boffito M, Dickinson L, Hill A, et al. Steady-state pharmacokinetics (PK) of saquinavir hard gel (SQV)/fosamprenavir (908) 1000/700 mg plus 100 mg and 200 mg of ritonavir (RTV) bid in HIV+ patients [poster no. 608]. 11th Conference on Retroviruses and Opportunistic Infections (CROI); 2004 Feb 8-11; San Francisco
36. Wire MB, Ballow C, Preston SL, et al. An assessment of plasma amprenavir (APV) pharmacokinetics (PK) following administration of two GW433908 (908) and ritonavir (RTV) BID regimens in combination with efavirenz (EFV) in healthy adult subjects (APV10010) [poster no. 431W]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle
37. AIDSmap news [online]. Available from URL: http:// www.aidsmap.com/news/ newsdisplay2.asp?newslD=2631 [Accessed 2004 Jun 16]
38. Panel on Clinical Practices for Treatment of HIV Infection convened by the US Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: July 14, 2003 [online]. Available from URL: http://aidsinfo.nih.gov/guidelines/adult/ AA_071403.pdf [Accessed 2003 Sep 8]
39. Bristol-Myers-Squibb. Reyataz™ (atazanavir sulfate) capsules: prescribing information and patient information (US)[online]. Available from URL: http://www.bms.com [Accessed, 2004 Apr 20]
40. Goldsmith DR, Perry CM. Atazanavir. Drugs 2003; 63 (16): 1679-93